Company Overview
Company Type: Public Company
Website: www.sernova.com
Number of Employees: -
Ticker: SVA (TSX)
Year Founded: 1998


Business Description
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells;a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform; and research collaboration with AstraZeneca PLC to evaluate novel potential therapeutic cell applications. The company was incorporated in 1998 and is headquartered in London, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
250.3
EBITDA
(36.8)
Total Enterprise Value
219.4
TEV/EBITDA
NM
EBIT
(37.1)
Cash & ST Invst.
31.0
P/Diluted EPS Before Extra
NM
Net Income
(35.5)
Total Debt
0.2
Price/Tang BV
10.3x
Capital Expenditure
(0.1)
Total Assets
33.2
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jul-31-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Oct-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.02)
(0.02)
(0.10)
(0.08)
(0.08)
Revenue (mm)
0.00
0.00
0.00
0.00
0.00
EBITDA (mm)
-
-
(24.60)
(23.77)
(23.98)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/EBITDA
NM
P/BV
3.90x

Non-Periodic Estimates

Recommendation
Outperform (1.75)
Target Price
4.14
Potential Upside
430.45%


Key Professionals
Name
Title
Pussinen, Cynthia 
CEO & Director
Toleikis, Philip M.
President, CTO, Director of Technology & Director
Swetlow, David 
Chief Financial Officer
Maret, Douglas 
Chief Science Officer
Barnes, Christopher 
Vice President of Investor Relations
Obochi, Modestus 
Chief Business Officer
Shannon, Frank 
Vice President of Clinical Development & Regulatory Affairs

Key Board Members
Name
Title
Whalen, Brett Alexander
Chairman
Pussinen, Cynthia 
CEO & Director
Toleikis, Philip M.
President, CTO, Director of Technology & Director
Parsons, James T.
Independent Director
Dufour, Jannette
Member of Scientific Advisory Board
King, George L.
Member of Scientific Advisory Board
Lillicrap, David 
Member of Scientific Advisory Board
Mahony, Daniel
Director
Paraskevas, Steven 
Member of Scientific Advisory Board
Patience, Clive 
Member of Scientific Advisory Board
Plettenberg, Bertram T. Von
Director
Sangha, Steven 
Director


Primary Industry Classification
Biotechnology


Primary Office Location
The Stiller Centre Suite 114 700 Collip Circle | London, ON | N6G 4X8 | Canada
Fax: 519 858 5099

Current and Pending Investors
2578606 Ontario Inc., Evotec SE (XTRA:EVT)

Prior Investors
International Cetec Investments Inc.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.80
Market Cap (mm)
250.3
Open
 0.79
Shares Out. (mm)
320.9
Previous Close
 0.78
Float %
85.8%
Change on Day
0.02
Shares Sold Short (mm)
-
Change % on Day
2.6%
Dividend Yield %
-
Day High/Low
 0.80/ 0.78
Diluted EPS Excl. Extra Items
(0.12)
52 wk High/Low
 1.28/ 0.69
P/Diluted EPS Before Extra
NM
Volume (mm)
0.03
Avg 3M Dly Vlm (mm)
0.08
Beta 5Y
1.57


 
Delayed Quote** | Last Updated on Oct-06-2023 12:20 PM (GMT-5)
TSX:SVA - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Mecca Medi-Tech Inc.
As of February 28, 2000, Mecca Medi-Tech Inc. was acquired by Pheromone Sciences Corp., in a reverse merger transaction. Mecca Medi-Tech Inc. is a capital pool company. The company is based in Vancouver, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-27-2022
Sep-01-2022
Private Placement
Target
Sernova Corp. (TSX:SVA)
Evotec SE (XTRA:EVT)

5.14
May-17-2022
May-17-2022
Private Placement
Target
Sernova Corp. (TSX:SVA)
Evotec SE (XTRA:EVT)

15.83
Feb-3-2021
Mar-1-2021
Public Offering
Target
Sernova Corp. (TSX:SVA)


15.83
Sep-09-2020
Sep-23-2020
Private Placement
Target
Sernova Corp. (TSX:SVA)
2578606 Ontario Inc.

2.74
Jun-08-2020
Jun-15-2020
Private Placement
Target
Sernova Corp. (TSX:SVA)


0.73
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-05-2023
Shareholder/Analyst Calls
Sernova Corp. - Shareholder/Analyst Call
Sep-29-2023
Product-Related Announcements
Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting
Sep-22-2023
Shareholder/Analyst Calls
Sernova Corp. - Shareholder/Analyst Call
Sep-07-2023
Product-Related Announcements
Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device
Sep-05-2023
Executive/Board Changes - Other
Sernova Corp. Announces Executive Changes


Advisors
Most Recent Auditor
KPMG Limited
Private Placement Advisors
Macquarie Private Wealth Inc., Macquarie Private Wealth Inc., Investment Banking Arm
Public Offering Advisors
Davidson & Company LLP, McMillan LLP


Most Recent Auditor
KPMG LLP - Klynveld Peat Marwick Goerdeler


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Research Capital Corporation
Uddin, Andre
Oct 05, 2023 11:27 AM
SVA
Full Steam Ahead
Reports
10
S&P Global Compustat

Oct 05, 2023 03:41 AM
SVA
Sernova Corp 2023_10_05
Reports
14
GlobalData

Oct 03, 2023 12:38 AM
SVA
Sernova Corp (SVA.TSE) - Financial and Strategic SWOT Analysis Review
Reports
203
H.C. Wainwright & Co.
Pantginis, Joseph
Sep 29, 2023 10:15 AM
SVA
Pipeline in a Device; Cell Pouch System Continues to Show Preclinical Efficacy in THR
Reports
9
GlobalData

Sep 20, 2023 01:18 AM
SVA
Sernova Corp (SVA.TSE) - Financial and Strategic SWOT Analysis Review
Reports
201
GlobalData

Sep 15, 2023 10:31 AM
SVA
Sernova Corp (SVA.TSE) - Medical Devices Product Pipeline Summary
Reports
78
Leede Jones Gable Inc
Loe, Douglas W.
Sep 15, 2023 05:36 AM
SVA
LJG: Healthcare & Biotechnology Weekly - September 15, 2023
Reports
11
Research Capital Corporation
Uddin, Andre
Sep 15, 2023 05:33 AM
SVA
Q3 - More Awaits
Initiation of Coverage*
6
Leede Jones Gable Inc
Loe, Douglas W.
Sep 08, 2023 05:33 AM
SVA
LJG: Healthcare & Biotechnology Weekly - September 8, 2023
Reports
9
S&P Global Compustat

Sep 07, 2023 03:26 AM
SVA
Sernova Corp 2023_09_07
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Angel, Tomas 

14,900,000

4.64

12.1

Mar-22-2023


Sangha, Steven 

12,166,900

3.79

9.9

Jul-28-2023


Toleikis B.A., M.Sc., Ph.D., Philip M.

5,273,598

1.64

4.3

Apr-25-2023


Millar, Betty Anne

4,008,700

1.25

3.2

Mar-22-2023


Whalen C.F.A., CFA, Brett Alexander

2,650,000

0.83

2.1

Jul-26-2023


Deol, Garry 

2,345,140

0.73

1.9

Mar-22-2023


Plettenberg, Bertram T. Von

1,576,600

0.49

1.3

Jul-28-2023


Dubreuil, Stephan 

670,275

0.21

0.5

Mar-22-2023


Holler MBA, Frank A.

666,666

0.21

0.5

Mar-08-2023


Bacha B.Sc., M.B.A., Jeffrey A.

614,980

0.19

0.5

Apr-25-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Whalen C.F.A., CFA, Brett Alexander
2,650,000
250,000
Next Edge Capital Corp.
165,000
55,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Sangha, Steven 
12,166,900
(122,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Cell Pouch (Future), iPSC Islet Custer (Future), Licensing of Sertolin (Future), Sertolin


Upcoming Events
Date/Time
Type
Oct-10-2023
Conferences
Oct-11-2023 5:30 PM (PST)
Company Conference Presentations
Jan-29-2024
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-29-2023
-
Sernova Corp. (TSX:SVA)
SEDAR
News Releases
649 KB
Sep-14-2023
-
Sernova Corp. (TSX:SVA)
SEDAR
News Releases
74 KB
Sep-13-2023
-
Sernova Corp. (TSX:SVA)
SEDAR
News Releases
438 KB
Sep-13-2023
Jul-31-2023
Sernova Corp. (TSX:SVA)
SEDAR
Interim Financial Statements
265 KB
Sep-07-2023
-
Sernova Corp. (TSX:SVA)
SEDAR
News Releases
582 KB
Sep-05-2023
-
Sernova Corp. (TSX:SVA)
SEDAR
News Releases
454 KB
Jul-28-2023
-
Sernova Corp. (TSX:SVA)
SEDAR
News Releases
137 KB
Jun-26-2023
-
Sernova Corp. (TSX:SVA)
SEDAR
News Releases
644 KB
Jun-22-2023
-
Sernova Corp. (TSX:SVA)
SEDAR
News Releases
662 KB
Jun-16-2023
-
Sernova Corp. (TSX:SVA)
SEDAR
News Releases
443 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Whalen C.F.A., CFA, Brett Alexander (Chairman)
Jul-26-2023
Common Shares
250,000
245,780
Open Market Acquisition
10.42
Multiple
Parsons CPA-CA, MAcc, James T. (Independent Director)
Sep-22-2022
Common Shares
10,000
3,546
Derivative Exercise and Retained Stock
3.64
Multiple
Bacha B.Sc., M.B.A., Jeffrey A. (Former Independent Director)
Sep-20-2022
Common Shares
16,666
5,980
Derivative Exercise and Retained Stock
2.79
Multiple
Toleikis B.A., M.Sc., Ph.D., Philip M. (President, CTO, Director of Technology & Director)
Sep-19-2022
Common Shares
45,002
16,211
Derivative Exercise and Retained Stock
0.86
Multiple
Holler MBA, Frank A. (Former Executive Chairman of the Board)
Jul-26-2022
Common Shares
83,333
30,960
Derivative Exercise and Retained Stock
14.29
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Whalen, Brett Alexander
Chairman
1 800 882 3213
519 858 5099

Pussinen, Cynthia 
CEO & Director
-
519 858 5099

Toleikis, Philip M.
President, CTO, Director of Technology & Director
(604) 961-2939
519 858 5099
philip.toleikis@sernova.com
Parsons, James T.
Independent Director
416-595-0627 x232
519 858 5099

Dufour, Jannette
Member of Scientific Advisory Board
-
519 858 5099
-
King, George L.
Member of Scientific Advisory Board
-
519 858 5099
-
Lillicrap, David 
Member of Scientific Advisory Board
-
519 858 5099

Mahony, Daniel
Director
44 20 7425 8436
519 858 5099
-
Paraskevas, Steven 
Member of Scientific Advisory Board
-
519 858 5099

Patience, Clive 
Member of Scientific Advisory Board
-
519 858 5099

Plettenberg, Bertram T. Von
Director
-
519 858 5099

Sangha, Steven 
Director
-
519 858 5099

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Pussinen, Cynthia 
CEO & Director
-
519 858 5099

Toleikis, Philip M.
President, CTO, Director of Technology & Director
(604) 961-2939
519 858 5099
philip.toleikis@sernova.com
Swetlow, David 
Chief Financial Officer
-
519 858 5099

Maret, Douglas 
Chief Science Officer
-
519 858 5099

Barnes, Christopher 
Vice President of Investor Relations
(905) 470-5483
(905) 470-4003

Obochi, Modestus 
Chief Business Officer
-
519 858 5099

Shannon, Frank 
Vice President of Clinical Development & Regulatory Affairs
-
519 858 5099

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
